AbCellera Biologics Inc. ABCL Operating lease right-of-use assets amortization expense
Operating lease right-of-use assets amortization expense at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s operating lease right-of-use assets amortization expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s operating lease right-of-use assets amortization expense?
- AbCellera Biologics Inc. (ABCL) reported operating lease right-of-use assets amortization expense of $1.82M in Q1 2026.
- How has AbCellera Biologics Inc.'s operating lease right-of-use assets amortization expense changed year-over-year?
- AbCellera Biologics Inc.'s operating lease right-of-use assets amortization expense increased by 42.6% year-over-year, from $1.27M to $1.82M.
- What is the long-term trend for AbCellera Biologics Inc.'s operating lease right-of-use assets amortization expense?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s operating lease right-of-use assets amortization expense has grown at a 24.3% compound annual growth rate (CAGR), from $2.79M to $6.65M.
- What does operating lease right-of-use assets amortization expense mean?
- This represents the systematic allocation of the cost of right-of-use assets related to operating leases over the lease term. It reflects the cost of utilizing leased facilities or equipment as part of the company's core operations. This metric is vital for understanding the true operational cost structure and the impact of lease accounting standards on the balance sheet.